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Abstract The proteasome inhibitors lactacystin and AcLLNal
induced p53-independent apoptosis in two human glioma cell
lines, and the apoptosis was accompanied by up-regulation of
immunoreactive wild-type p53, p21Waf1, Mdm2, and p27Kip1.
Pretreatment with cycloheximide decreased the induction of cell
death independently of p53 protein status, suggesting that the up-
regulation of short-lived proteins is associated with proteasome
inhibitor-induced apoptosis. Caspase-3-like proteases were acti-
vated in the proteasome inhibitor-mediated apoptosis, and the
induction of cell death was inhibited more effectively in the
presence of z-VAD.fmk than in the presence of Ac-DEVD.fmk,
suggesting that caspases other than caspase-3 are involved.
Nonetheless, there were no significant alterations in levels of
immunoreactive Bcl-2, Bcl-xL, Bax, Bad, and Bak, nor any
evidence of cytochrome c release into cytosol and dissipation of
v8m. Thus, the proteasome inhibitor-induced apoptosis is
mediated by a mitochondria-independent mechanism, and the
once activated caspase-3 does not cause the cytochrome c release
and the v8m disruption.
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1. Introduction
The caspase family is implicated as a central component of
the proteolytic machinery during apoptotic cell death [1]. In
contrast, much less attention has been paid so far to the
potential role of proteasomes in apoptosis. In higher eukary-
otic cells, the proteasome is involved in the ATP/ubiquitin-
dependent proteolysis of most of the nuclear and cytosolic
proteins and in particular of short-lived proteins critical for
cell proliferation and cell cycle regulation. Examples include
the tumor suppressor protein p53 [2^4], various cyclins [5],
and cyclin-dependent kinase inhibitor p27Kip1 [6,7]. The natu-
ral product lactacystin, which speci¢cally inhibits proteolytic
activities of the proteasome [8], has been shown to induce
apoptotic cell death in human monoblast U937 cells [9], and
peptide aldehyde inhibitors of proteasome AcLLNal have also
been shown to induce apoptosis in human prostate adenocar-
cinoma [10] and U937 cells [11]. In addition, other proteasome
inhibitors cause apoptosis in human T-cell leukemia MOLT-4
cells [12], human leukemic HL60 cells [13], Rat-1 cells [14],
and PC12 cells [14]. Nevertheless, proteasome inhibitors such
as lactacystin and MG132 have been reported to protect thy-
mocytes, T cell hybridomas, and PC12 cells against a number
of di¡erent apoptosis inducers [15^18], and non-proliferating
Rat-1 cells were no longer susceptible to apoptosis induced by
proteasome inhibitors [14]. In addition, certain forms of apop-
tosis in quiescent cells such as lymphocytes [19] and thymo-
cytes [15], or terminally di¡erentiated cells such as sympa-
thetic neurons [16], depended on a functional proteasome.
However, neurons and thymocytes did not di¡er from other
cells in being susceptible to apoptosis when persistently ex-
posed to proteasome inhibitors [15,16], and inhibition of the
proteasome still induced apoptosis of non-proliferating PC12
cells that had been induced to di¡erentiate by treatment with
nerve growth factor [14]. These results indicate that cell pro-
liferation is one but not the only determinant of the cellular
response to inhibition of the proteasome. It appears that the
proteasome can function to promote either cell survival or
death, depending on both proliferative state and cell type-
speci¢c factors.
The speci¢cs of the proteolytic cascades may vary depend-
ing on cell type and stimulus used to trigger apoptosis. Pro-
teasome inhibitor-induced apoptosis is reported to be associ-
ated with activation of caspase-3 [13,20]. The major
mechanism for activating caspases is related to some of the
changes that occur in mitochondria during apoptosis [21].
Another mechanism for initiating the proteolytic cascade is
induced by ligation of TNF receptors, Fas/APO-1/CD95
[22,23], or granzyme B [24,25], and is directly coupled to cas-
pase activation without any evidence of involvement of mito-
chondria. Our data show that proteasome inhibitor activates
caspase-3-like proteases without any evidence of release of
cyt c from mitochondria and collapse of v8m, suggesting
that proteasome inhibitor-induced apoptosis is associated
with mitochondria-independent activation of caspase-3.
2. Materials and methods
2.1. Glioma cell culture
Two human glioma cell lines, wild-type p53-positive U-87MG [26]
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and mutant p53-positive T98G cells [27], were obtained from Amer-
ican Type Culture Collection (Rockville, MD, USA), and were main-
tained in DMEM supplemented with 10% FCS and antibiotics
(100 U/ml penicillin and 100 Wg/ml streptomycin) in a humidi¢ed
atmosphere of 5% CO2 and 95% air at 37‡C. Cells were exposed to
50 WM lactacystin or 50 WM AcLLNal (Cosmo Bio Inc., Tokyo,
Japan) for the indicated times, and were stained with 2.5 Wg/ml
Hoechst 33258 after ¢xation with 4% paraformaldehyde. Apoptotic
cells were assessed based on the morphological features characteristic
of apoptosis and electrophoretic patterns of oligonucleosomal DNA
laddering, and the viability of the cells was con¢rmed by the trypan
blue dye exclusion method.
2.2. Determination of DNA fragmentation
DNA was prepared from cells as described previously [28]. The
resulting DNA preparation was analyzed by 1.5% agarose gel electro-
phoresis in TBE bu¡er (89 mM Tris-borate bu¡er, pH 8.0/89 mM
boric acid/22 mM EDTA) containing 0.5 Wg/ml of ethidium bromide
at 100 V/cm for 30 min.
2.3. Immunoblot analysis
Cells were lysed in a lysis bu¡er (20 mM Tris-HCl at pH 7.4/150
mM NaCl/0.5% NP-40/1 mM EDTA/50 Wg/ml leupeptin/30 Wg/ml
aprotinin/1 mM PMSF), and then centrifuged at 15 000Ug for
10 min. Equivalent amounts of cell lysates were heated in 2Uloading
bu¡er at 95‡C for 3 min, then electrophoresed in 12% SDS-polyacryl-
amide gel, except for immunoblotting of PARP in which 8% SDS-
polyacrylamide gel was used, and transferred onto PVDF membranes.
The membranes were incubated with primary antibody against both
wild-type and mutant p53 (Oncogene Science, Cambridge, MA,
USA), p21Waf1 (Oncogene Science), Mdm2 (Santa Cruz, Santa Cruz,
CA, USA), p27Kip1 (Santa Cruz), Bcl-2 (Pharmingen, San Diego, CA,
USA), Bcl-x (Transduction, Lexington, KY, USA), Bax (Mobio, Na-
goya, Japan), Bad (Transduction), Bak (Santa Cruz), p10 subunit of
caspase-1 (Santa Cruz), p12 subunit of caspase-3 (Santa Cruz), PARP
(a kind gift from Dr. Guy G. Poirier, CHUL Research Center, Que-
bec, Que., Canada), cyt c (Pharmingen), and cytochrome oxidase
(Molecular Probes, Eugene, OR, USA), washed, and blotted with
species-speci¢c biotinylated secondary antibodies (Vector, Burlin-
game, CA, USA) and then with HRP-streptavidin (Vector). The mem-
brane was then developed in ECL reagent (Amersham, Arlington
Heights, IL, USA) and exposed to X-ray ¢lm.
2.4. Cytochrome c release into cytosol
Cells were incubated in bu¡er A (20 mM HEPES, pH 7.5/10 mM
KCl/1.5 mM MgCl2/1 mM EDTA/1 mM EGTA/1 mM DTT/0.1 mM
PMSF) containing 250 mM sucrose and homogenized with 10 strokes
of a Te£on homogenizer. After centrifugation of homogenates twice
at 750Ug for 10 min at 4‡C, the supernatants were centrifuged at
10 000Ug for 15 min at 4‡C. The resulting supernatants and pellets
were frozen at 380‡C as S10 cytosolic and mitochondrial fractions,
respectively. In addition, the supernatants of the 10 000Ug spin were
further centrifuged at 100 000Ug for 1 h at 4‡C, and the resulting
supernatants were also frozen at 380‡C as S100 cytosolic fraction.
Cyt c in mitochondrial and cytosolic fractions was immunologically
probed with anti-cyt c monoclonal antibody, and contamination from
mitochondria was examined by immunoblotting of cytochrome oxi-
dase.
2.5. Measurement of mitochondrial membrane potential
Cells were incubated for 15 min in cultured medium at 37‡C with
50 nM DiOC6(3) (Molecular Probes, Inc.) for measurement of the
inner mitochondrial membrane potential (v8m). As a positive control
for v8m loss, cells were incubated at the same time with the uncou-
pling agent mCICCP (50 WM), a protonophore, which disrupts v8m.
Cells were washed once with PBS, collected by centrifugation at
1000Ug, and stored in the dark at 4‡C prior to analysis by £ow
cytometry using excitation of a single 488 nm argon laser. Data ac-
quisition and analysis were performed using the CellFit software.
Forward scatter, perpendicular scatter and DiOC6(3) £uorescence
were measured with a 530/15 nm band pass ¢lter. At least 10 000
events were collected per sample, with DiOC6(3) £uorescence recorded
as logarithmic ampli¢ed data.
3. Results and discussion
3.1. Proteasome inhibitors induce apoptosis in glioma cells
To determine adequate concentrations of lactacystin or
AcLLNal to induce glioma cell death, 10^100 WM lactacystin
or AcLLNal were given for 72 h. The induction of the cell
death was dose-dependent, and 50 WM lactacystin or 50 WM
AcLLNal was chosen in the present experiment (cell viability
during treatment with lactacystin or AcLLNal is shown in
Fig. 5). During the treatment with lactacystin or AcLLNal,
both U-87MG and T98G cells gradually showed apoptotic
morphological features (Fig. 1): cell shrinkage and surface
blebbing by phase contrast images as well as nuclear con-
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Fig. 1. Photomicrographs showing representative apoptotic morpho-
logical features induced by lactacystin or AcLLNal in two human
glioma cell lines (U-87MG and T98G): cell shrinkage and surface
blebbing by phase contrast images (lines 1 and 3) as well as nuclear
condensation and fragmentation by Hoechst 33258 stain (lines 2
and 4). U-87MG cells were exposed to 50 WM lactacystin or 50 WM
AcLLNal for 48 h, while T98G cells were exposed to 50 WM lacta-
cystin or 50 WM AcLLNal for 24 h. Magni¢cation U86.
Fig. 2. Electrophoresis showing the induction of oligonucleosomal
DNA laddering by AcLLNal treatment for 40 h in U-87MG cells
(lane 2) and for 18 h in T98G cells (lane 4), or by lactacystin treat-
ment for 30 h in U-87MG (lane 5) and for 15 h in T98G (lane 9).
The induction of DNA laddering by lactacystin is not blocked in
the presence of 100 WM Ac-YVAD.cmk (lanes 6 and 10) but is
completely blocked in the presence of 100 WM Ac-DEVD.fmk (lanes
7 and 11) or 100 WM z-VAD.fmk (lanes 8 and 12). The formation
of oligonucleosomal DNA fragments was determined by agarose gel
electrophoresis. The results are from a representative study per-
formed three times with comparable outcomes. Lanes 1 and 3, con-
trol ; lane M, DNA size markers.
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densation and fragmentation by Hoechst 33258 stain. In ad-
dition, unambiguous electrophoretic patterns of oligo-
nucleosomal DNA laddering were observed in both U-
87MG and T98G cells (Fig. 2), indicating that lactacystin
and AcLLNal induce apoptotic cell death. AcLLNal is also
a better inhibitor of calpain than any of the catalytic activities
of the proteasome, and complete inhibition of calpain is ob-
tained with 10 WM AcLLNal [29]. However, 0.1^10 WM cal-
peptin, a speci¢c inhibitor of calpain, which was enough high
in concentration to inhibit the activity of calpain [30], did not
induce apoptosis in the present glioma cell lines (unpublished
data). In addition, the concentration of AcLLNal used in the
present study is comparable to that required for induction of
apoptosis in human adenocarcinoma cells [10] and U937 cells
[11]. It is suggested, therefore, that the AcLLNal-induced
apoptosis is due to the inhibition of proteasome but not cal-
pain.
3.2. Inhibition of proteasomal activity is accompanied by
accumulation of p53, p21Waf1, Mdm2, and p27Kip1
Since the anti-human p53 antibody used in the present
study recognizes both wild-type and mutant p53 [31], p53
visualized by the present immunoblot analysis indicates
wild-type in U-87MG cells and mutant in T98G cells. Immu-
noreactive wild-type p53, cyclin-dependent kinase inhibitor
p21Waf1, and p53 negative regulator Mdm2 in U-87MG cells
were simultaneously up-regulated at least as early as 6 h after
treatment with lactacystin or as early as 8 h following treat-
ment with AcLLNal (Fig. 3), but Mdm2 was degraded 18 h
after lactacystin treatment and 24 h after AcLLNal treatment,
indicating that the accumulated p53 is biologically active,
based on transactivation of the p53 target genes encoding
p21Waf1 and Mdm2 [32^35]. A similar accumulation of wild-
type p53 has been reported in apoptosis of MOLT-4 cells
induced by the proteasome inhibitor LLLal [4,12] and in
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Fig. 3. Immunoblot analysis showing protein levels of p53, p21Waf1, Mdm2, p27Kip1, Bcl-2, Bcl-xL, Bax, Bad, and Bak. Human glioma cells
(U-87MG and T98G) were exposed to 50 WM lactacystin for 24 h in U-87MG and for 12 h in T98G, or to 50 WM AcLLNal for32 h in
U-87MG and for 15 h in T98G, and steady-state levels of p53, p21Waf1, Mdm2, p27Kip1, Bcl-2 Bcl-xL, Bax, Bad, and Bak were monitored by
immunoblot analysis. The results are from a representative study performed three times with comparable outcomes.
Fig. 4. Immunoblot analysis showing no activation of caspase-1 but activation of caspase-3 and cleavage of PARP in human glioma cells
(U-87MG and T98G). Cells were exposed to 50 WM lactacystin for 30 h in U-87MG and for 15 h in T98G, or to 50 WM AcLLNal for 40 h in
U-87MG and for 18 h in T98G. Formation of an active 10 kDa caspase-1 fragment was not detected during exposure to lactacystin or AcLL-
Nal, suggesting no activation of caspase-1, whereas an active 12 kDa caspase-3 fragment was formed in both U-87MG and T98G cells, indicat-
ing activation of caspase-3. Cleavage of PARP into the speci¢c 85 kDa apoptotic fragment was concomitant with the activation of caspase-3.
Similar results were achieved in three separate experiments.
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apoptosis of Rat-1 and PC12 cells induced by the proteasome
inhibitors PSI and MG115 [14]. These results are consistent
with evidence that the proteasome is involved in the ubiquitin-
dependent proteolytic pathway through which wild-type p53
is degraded [2^4]. Wild-type p53 played a key role in PSI- or
MG115-induced apoptosis, because the apoptosis was inhib-
ited by expression of dominant-negative p53 [14]. However,
the present lactacystin- or AcLLNal-mediated apoptosis oc-
curs even in mutant p53-positive T98G cells, suggesting that
proteasome inhibitor-induced apoptosis is rather p53-inde-
pendent. Immunoreactive levels of mutant p53 in T98G cells
remained unchanged by treatment with lactacystin or AcLL-
Nal, but immunoreactive Mdm2 in T98G cells was degraded
in a later stage of the treatment (Fig. 3) and immunoreactive
p21Waf1 in T98G cells became detectable as early as 3 h after
the treatment (Fig. 3). The later degradation of Mdm2 by
lactacystin or AcLLNal treatment in U-87MG and T98G cells
may be due to proteolysis by activated caspase-3 [36]. Up-
regulation of p21Waf1 has been reported recently in the human
breast cancer cell lines MCF-7 and MDA-MB-468 undergoing
apoptosis induced by 10-hydroxycamptothecin and campto-
thecin through p53-dependent and -independent pathways
[37]. In addition to p21Waf1, another inhibitor of cyclin-de-
pendent kinase, p27Kip1, was also up-regulated independently
of p53 protein status at least 6 h after lactacystin treatment or
8 h after AcLLNal treatment (Fig. 3), consistent with previous
reports that the proteasome is involved in the ubiquitin-de-
pendent proteolysis of p27Kip1 [6,7,13].
To examine whether the up-regulation of short-lived pro-
teins in response to the inhibition of the proteasome is impli-
cated in apoptosis, glioma cell lines were pretreated for 2 h
with 5 Wg/ml cycloheximide and then grown in the presence of
proteasome inhibitor and 1 Wg/ml cycloheximide. The pre-
treatment with cycloheximide increased the cell viability
from 71.1 þ 2.6% to 95.6 þ 1.2% at 48 h after AcLLNal treat-
ment in U-87MG and from 67.6 þ 3.3% to 97.4 þ 1.0% at 24 h
after AcLLNal treatment in T98G cells, suggesting that the
accumulation of short-lived proteins is associated with protea-
some inhibitor-mediated apoptosis. The accumulation of
short-lived proteins such as p53 and p27Kip1 in response to
the inhibition of ubiquitin-dependent degradation has been
reported to cause caspase-3 and -6-independent apoptosis
[38]. Recently, the overexpression of p27Kip1 alone has been
reported to trigger apoptosis in several di¡erent human cancer
cell lines as well as Rat-1 and IMR90 (human lung ¢bro-
blasts) cells [39,40]. Results from p21Waf1 knockout animals
and other experiments show unequivocally that p21Waf1 is not
required for apoptosis [41,42].
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Fig. 5. E¡ects of z-VAD.fmk and Ac-DEVD.fmk on cell viability.
A: z-VAD.fmk (100 WM) or Ac-DEVD.fmk (100 WM) was added to
the culture medium 60 min prior to addition of 50 WM lactacystin
or 50 WM AcLLNal and thereafter every 24 h. After treatment with
either proteasome inhibitor for the indicated times, U-87MG and
T98G cells were subjected to immunoblotting of PARP and exami-
nation of cell viability. In a representative immunoblot of PARP,
the induction of the 85 kDa PARP apoptotic fragment by lactacys-
tin treatment for 30 h in U-87MG (lane 2) and for 15 h in T98G
(lane 5) or by AcLLNal treatment for 40 h in U-87MG (lane 8)
and for 18 h in T98G (lane 11) is blocked in the presence of
z-VAD.fmk in U-87MG (lanes 3 and 9) and in T98G (lanes 6 and
12). B: Cell viability graphs: open squares, control; open diamond,
treatment with lactacystin or AcLLNal; closed circles, treatment
with lactacystin or AcLLNal in the presence of z-VAD.fmk; crosses,
treatment with lactacystin or AcLLNal in the presence of Ac-
DEVD.fmk; vertical lines, standard deviations. The data shown
were obtained from three separate experiments.
Fig. 6. Immunoblot analysis of cyt c and cytochrome oxidase (cyt
ox) in mitochondrial (A) and S100 (B) or S10 (C) cytosolic fractions
of U-87MG and T98G cells treated with 50 WM AcLLNal for the
time indicated. Immunoreactive cyt c and cyt ox are detected in mi-
tochondrial fractions of both cells and remain unchanged in levels
during AcLLNal treatment. Immunoreactive cyt ox was not detected
in S10 and S100 cytosolic fractions of both cells during AcLLNal
treatment, while immunoreactive cyt c was detected in S10 cytosolic
fractions but not in S100 cytosolic fractions of both cells and re-
mained unchanged in level during AcLLNal treatment. Similar re-
sults were achieved in three independent experiments of AcLLNal-
and lactacystin-induced apoptosis. Immunoreactive cyt c in S10 cy-
tosolic fractions of both cells is increased in calphostin C-induced
apoptosis, as shown in the lowermost immunoblot.
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3.3. Inhibition of proteasomal activity induces activation of
caspase-3-like proteases
Immunoblot analysis of caspase-1 showed no formation of
active 10 kDa caspase-1 fragment in both U-87MG and T98G
cells during treatment with lactacystin or AcLLNal (Fig. 4),
suggestive of no activation of caspase-1. In contrast, immu-
noreactive 32 kDa procaspase-3 in both U-87MG and T98G
cells was degraded into an active 12 kDa caspase-3 fragment
by proteolytic processing as early as 18 h in U-87MG cells
and 9 h in T98G cells after treatment with lactacystin or as
early as 24 h in U-87MG cells and 9 h in T98G cells after
treatment with AcLLNal (Fig. 4), and the total amounts of
32 kDa procaspase-3 and 12 kDa caspase-3 fragment re-
mained unchanged during treatment with either proteasome
inhibitor, suggesting activation of caspase-3 [43^46]. In addi-
tion, a C-terminal 85 kDa PARP apoptotic fragment was
generated concomitantly with the formation of the active
12 kDa caspase-3 fragment in both U-87MG and T98G cells
(Fig. 4), supporting activation of caspase-3-like proteases [47^
49]. Two tetrapeptide derivatives, Ac-YVAD.cmk and Ac-
DEVD.fmk, which are relatively selective inhibitors of cas-
pase-1 and -3, respectively [45], were used to preferentially
block one or the other group of cysteine proteases. Ac-
YVAD.cmk (100 WM), Ac-DEVD.fmk (100 WM), or
z-VAD.fmk (100 WM; broad-spectrum caspase inhibitor)
was added to the culture medium 60 min prior to the treat-
ment with lactacystin or AcLLNal and thereafter every 24 h.
A marked inhibition of caspase-3-like proteases in the pres-
ence of z-VAD.fmk was con¢rmed by the absence of the C-
terminal 85 kDa PARP fragment induced by lactacystin or
AcLLNal, as shown in Fig. 5, and the induction of oligonu-
cleosomal DNA laddering by lactacystin could be completely
blocked by treatment with Ac-DEVD.fmk or z-VAD.fmk in
both U-87MG and T98G cells but not by treatment with Ac-
YVAD.cmk (Fig. 2), con¢rming again the activation of cas-
pase-3- but not caspase-1-like proteases. The induction of cell
death was delayed more e¡ectively in the presence of
z-VAD.fmk than in the presence of Ac-DEVD.fmk, as shown
in Fig. 5, suggesting that caspases other than caspase-3 are
involved in the proteasome inhibitor-mediated apoptosis.
3.4. Inhibition of proteasomal activity induces no cyt c release
or mitochondrial dysfunction
There was no evidence of signi¢cant changes in immuno-
reactive levels of Bcl-2, Bcl-xL, Bax, Bad, and Bak in lacta-
cystin- or AcLLNal-induced apoptosis of both U-87MG and
T98G cells (Fig. 3). Bcl-2 and Bcl-xL, located on the outer
mitochondrial membrane, are reported to inhibit cyt c release,
thereby blocking the apoptotic process [50^52]. Therefore, we
examined by immunoblot analysis whether cyt c is released
from mitochondria into cytosol in lactacystin- or AcLLNal-
induced apoptosis. Immunoreactive cyt c was detected in S10
cytosolic fractions but not in S100 cytosolic fractions of U-
87MG and T98G cells during AcLLNal treatment, and the
immunoreactive levels of cyt c in S10 cytosolic and mitochon-
drial fractions were not changed before and after the activa-
tion of caspase-3 (Fig. 6), suggesting no release of cyt c. The
presence of cytochrome oxidase in the mitochondrial fraction
and its absence in the S10 and S100 cytosolic fractions seem
to verify the adequacy of the present subcellular fractionation.
In addition, cyt c release into cytosol was shown by immuno-
blot analysis of S10 and S100 cytosolic fractions and immu-
nohistochemistry in calphostin C-induced apoptosis of the
same glioma cell lines (Fig. 6 and unpublished data, respec-
tively).
DiOC6(3)-based measurement of inner mitochondrial mem-
brane potential demonstrated no dissipation of v8m before
the activation of caspase-3, as shown in AcLLNal-induced
apoptosis (Fig. 7). Acute exposure of cells to the protono-
phore mCICCP con¢rmed that the DiOC6(3) staining was
dependent on the inner mitochondrial membrane potential,
thus verifying the speci¢city of this assay. Thus, the absence
of v8m dissipation in the present proteasome inhibitor-in-
duced apoptosis is associated with the absence of both cyt c
release into cytosol and changes of Bcl-2-related proteins.
Downstream caspases can become activated generally via at
least two pathways: one dependent on mitochondria and an-
other on the upstream caspases, such as those activated by
Fas and some other TNF family receptors. The cytoplasmic
domains of some TNF receptors, such as Fas/APO-1/CD95,
are linked to caspases via FADD/MORT-1 adaptor protein
[53,54]. After binding of Fas-ligand, caspase-8 and possibly
caspase-10 are recruited to the cytoplasmic domain of the
Fas receptor and become activated by proteolysis [25,26].
Once activated in cells, these upstream caspases can then
cleave and activate certain downstream caspases, such as cas-
pase-3, which are directly responsible for the proteolytic cleav-
age of cell death substrate proteins and the actual apoptotic
demise of the cell [55^57]. It is important to recognize, how-
ever, that cross-talk between these two pathways is extensive.
For example, upstream and downstream caspases, once acti-
vated, can act on yet unknown substrates in the mitochondrial
membrane, thereby inducing the dissipation of v8m and the
release of apoptogenic proteins [58^60]. However, in the
present proteasome inhibitor-induced apoptosis, neither cyt c
release nor v8m loss is observed not only before but also after
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Fig. 7. U-87MG and T98G cells were treated with 50 WM AcLLNal
for the indicated times and incubated with DiOC6(3), followed by
FACS analysis. Data for DiOC6(3) represent log £uorescence versus
relative cell number. As a control for speci¢city of DiOC6(3) label-
ing, an aliquot of the control untreated cells was exposed to the
protonophore mCICCP for 15 min prior to incubation with
DiOC6(3). Similar results were obtained in three separate experi-
ments of AcLLNal- and lactacystin-induced apoptosis. FL, £uores-
cence.
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the activation of caspase-3 (Figs. 6 and 7). Thus, the pro-
teasome inhibitor induces mitochondria-independent apopto-
sis.
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